Art Schuermans

What does the circulating proteome teach us about common heart diseases? Thrilled to share our analysis identifying new biomarkers, drug targets, and prediction models for these conditions. Co-led by @APournamdari, with @mchonig and @pnatarajanmd nature.com/articles/s4416… (1/x)

Excited to share our preprint led by @AeronSmallMD M. Yu @btakiy A. Georges & with @n_bouatianaji describing the genetic architecture of mitral valve prolapse across 2.2M individuals, integrating mitral valve apparatus & extra-valvular multi-omics - New therapeutic hypotheses nominated in MVP, myocardial fibrosis, & subclinical arrhythmia traits medrxiv.org/content/10.648… @medrxivpreprint

Thanks to Panagiotis Zangas for leading this and to @artschuermans for his insights. 🔗link to the paper: sciencedirect.com/science/articl…

Last year, we developed a genetic proxy of IL-6 signaling inhibition that we showed to predict reductions in atherosclerotic cardiovascular disease risk. Now, we also show reductions in risk of heart failure (both with preserved and reduced ejection fraction).

New online! Reframing atherothrombosis through the inflammation hypothesis dlvr.it/TRwLyK

Pleased to share our new @Circ_Gen article: Dr. Peter Libby and I present the spectrum of patients referred to cardiology for clonal hematopoiesis, define context- and biology-based categories, and outline a structured approach to CV evaluation and management Link below

Happy to share this "journal club" on one of the first studies linking inflammation to atherosclerotic disease. I discuss Ridker et al.'s 1997 analysis on CRP and ischemic events: doi.org/10.1056/nejm19… Read it below - published today at @NatRevCardiol: doi.org/10.1038/s41569…

Deeply honored to receive the JACC Parmley Prize 🏆 for our paper on Colchicine & Clonal Hematopoiesis. 🙏🏼to LiYing Xue, all co-authors, and for the amazing mentorship of @mchonig , S.El Messaoudi & J.H.Cornel.@JACCJournals @broadinstitute @radboudumc_weet @ACCinTouch #ACC26

Lp(a)-related VTE risk is not uniform & appears hormone-dependent: signal in premenopausal👩‍🦰and postmenopausal👩‍🦰on MHT, but not in👨‍🦰. Sim pub with #ACC.26 @ehj_ed. Congrats @daniel_ezt and 🙏 to co-authors & my co-senior author, mentor & friend @mchonig  academic.oup.com/eurheartj/adva…

Huge congrats to @NiekMohamma @radboudumc for receiving this year's @JACCJournals JACC Parmley Prize for his work on colchicine and clonal hematopoiesis #CHIP 🩸🧬 in LoDoCo2 ❤️‍🔥(jacc.org/doi/10.1016/j.…) and to all of the honorees at ACC26 (acc.org/About-ACC/Pres…)

Great editorial from @PamTaubMD @hsbhatia here: academic.oup.com/eurheartj/adva… 🙏 to co-senior @mapabonp + co-authors including @NiekMohamma @artschuermans @DrM_ODonoghue @bbikdeli @ZhiYu_ACGT @pnatarajanmd @AniruddhPatelMD + others @MGHHeartHealth

Now in @ehj_ed #EHJ simutaneous with #ACC26, our analysis of Lp(a) and VTE risk led by ⭐️🇧🇪 @daniel_ezt Take-🏠: Elevated Lp(a) is associated w/ ⬆️ VTE 🩸 in high-estrogen states (premenopausal 👭, + postmenopausal 👭 using hormone therapy) Paper here: academic.oup.com/eurheartj/adva…

Our manuscript led by @NakaoTetsushi @skoyamamd - a comprehensive characterization of leukocyte telomere length (LTL), a hallmark of biological aging across the US nature.com/articles/s4158… @NatureGenet Quick summary of lessons learned:

Thrilled to launch my computational genomics lab at the Division of Cardiovascular Medicine @BrighamWomens @MGBResearchNews @harvardmed @broadinstitute 🚀 We tackle genomic aging, inflammation & cardiovascular disease using population-scale genomics.

Colchicine reduces competitive advantage of clonal hematopoiesis (esp TET2) in COLCOT ahajournals.org/doi/abs/10.116… @CircAHA Similar to LoDoCo2 jacc.org/doi/10.1016/j.… @JACCJournals Our prior work in mice & human biobanks suggests that colchicine may be effective in reducing TET2 CHIP-associated CVD risk academic.oup.com/eurheartj/arti… @ESC_Journals

RESEARCH ARTICLE: LV Mass in Children With Extremely Low Birth Weight Is Lower But More Sensitive to Increased Blood Pressure @artschuermans @jasta49 ahajrnls.org/4c8ZWcR

🗞️ HFpEF isn’t about weak contraction but trapped reserve - when stroke volume stalls, heart rate must run free. A story of 🦒, 🐦 and 🐋. @Ph_Bertrand

📣 My team at @MGHHeartHealth @broadinstitute is growing: • Postdoc (PhD; human 🧬 & multi-omics) • Research fellow (clinical trials & epi; 2-yr) • Computational associate Join a collaborative, high-impact 🫀 precision medicine team. DM or email (mhonigberg@mgb.org)

Fantastic holiday party / “Yankee swap” 🎁🔄🎁 held jointly with the @pnatarajanmd @aklfahed @ZhiYu_ACGT labs at @MGHHeartHealth @broadinstitute. Lucky to work and collaborate with this amazing crew!

More evidence-based disease mechanisms = less #stigma for Long COVID patients! 👇👇👇👇 Human #genetics implicate thromboembolism in the pathogenesis of #LongCOVID in individuals of European ancestry. Nature Cardiovasc Res doi.org/10.1038/s44161…

Extended thank you to: @DrMArdissino, @VilmaAho, @JefVandenEynde, @ben_b_sun, @MariosGeorgakis, @PHOSP_COVID, @johanvawe, @BR_CMR, @hanna_ollila, @stevesphd, @pnatarajanmd, @mchonig, and everyone without taggable account!

Human genetic data suggest a link between thromboembolic pathways and long COVID 🩸 Happy to see our study published today in @NatureCVR: nature.com/articles/s4416… Super-thanks to @VerhammePeter, @AndreasVerstrae, @t_vanassche, @KathleenFreson, and many many more!